Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2112712 | Cancer Letters | 2014 | 8 Pages |
Abstract
Fibroblast growth factor receptor (FGFR) tyrosine kinases have been regarded as a target for cancer treatment, and there is much interest in inhibiting FGF/FGFR signaling by small molecules as a therapeutic approach to cancer. Generally, inhibitors mimics ATP structure and block the binding between ATP and FGFR kinase. Here, two novel, non-ATP-competitive, selective, irreversible FGFR1 inhibitors, A114 and A117, were identified via kinase inhibitory assay from 156 synthetic bisaryl-1,4-dien-3-one derivatives. A “DFG-OUT” inactive conformation binding mode with FGFR1 was predicted by molecular docking. A114 and A117 showed significant anti-tumor activity both in vitro and in vivo via targeting FGFR1.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yi Wang, Yuepiao Cai, Jiansong Ji, Zhiguo Liu, Chengguang Zhao, Yunjie Zhao, Tao Wei, Xueqian Shen, Xiuhua Zhang, Xiaokun Li, Guang Liang,